We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced promising preliminary data from an independent study that evaluated the booster dose of its single-shot COVID-19 vaccine, Ad26.COV2.S, administered at six months after a two-dose primary regimen of Pfizer (PFE - Free Report) and BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The study included a subset of participants in a phase II study — COV2008 — that is being sponsored by J&J and is conducted by Beth Israel Deaconess Medical Center.
Data from the study demonstrated that the administration of the booster dose of J&J’s vaccine-elicited neutralizing and binding antibody levels at week four post administration to same after a booster dose of Pfizer and BioNTech’s Comirnaty. Moreover, J&J’s booster dose also resulted in a greater increase in T-cell responses compared to Comirnaty.
Please note that while neutralizing antibodies help in blocking infection, T-cell destroys infected cells.
This preliminary data is also supported by an initial data from another clinical study — UK COV-BOOST — that evaluated J&J’s COVID-19 vaccine’s booster dose in participants who have received immunization with Pfizer and BioNTech’s Comirnaty or AstraZeneca’s (AZN - Free Report) COVID-19 vaccine, ChAdOx1 nCov-19, in their primary vaccination regimen. Data from the UK COV-BOOST study also demonstrated an increase in both antibody and T-cell responses following J&J’s booster dose.
We note that AstraZeneca is one of the early players to market a COVID-19 vaccine in the world. However, AZN is yet to receive authorization for its vaccine in the United States. AstraZeneca produced the vaccine at cost amid the pandemic. The vaccine generated $1.05 billion in revenues for AstraZeneca in the first nine months of 2021.
This year so far, J&J’s shares have risen 1.2% compared with an increase of 12.3% for the industry.
Image Source: Zacks Investment Research
J&J is a late entrant in the COVID-19 vaccine race. The company’s vaccine was first authorized for emergency use in the United States in February 2021. It expects $2.5 billion in revenues from the COVID-19 vaccine in 2021, significantly less than Pfizer’s $36 billion from its COVID-19 vaccine in the same period.
However, J&J’s booster dose was the first to receive emergency use authorization in the United States in October for all adults. Moreover, the recent preliminary data from the phase II study supports the use of J&J’s booster dose in people who have received initial vaccination with Comirnaty for better protection.
We note that the FDA had authorized the use of mix and match or heterologous administration of the booster doses in October that allows the administration of a booster dose of any authorized COVID-19 vaccine, irrespective of the primary vaccination regimen. This authorization of heterologous administration should ease the concerns related to the use of a different booster jab than the initial regimen.
With the majority of the population in the United States having received primary vaccination, the main revenue driver for the COVID-19 vaccine makers will come from the sale of booster doses. Clinical data supporting better protection with J&J’s booster dose may help the company drive the supply of booster doses higher next year. This may result in higher additional revenues for J&J from the COVID-19 vaccine next year.
Image: Bigstock
J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty
Johnson & Johnson (JNJ - Free Report) announced promising preliminary data from an independent study that evaluated the booster dose of its single-shot COVID-19 vaccine, Ad26.COV2.S, administered at six months after a two-dose primary regimen of Pfizer (PFE - Free Report) and BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The study included a subset of participants in a phase II study — COV2008 — that is being sponsored by J&J and is conducted by Beth Israel Deaconess Medical Center.
Data from the study demonstrated that the administration of the booster dose of J&J’s vaccine-elicited neutralizing and binding antibody levels at week four post administration to same after a booster dose of Pfizer and BioNTech’s Comirnaty. Moreover, J&J’s booster dose also resulted in a greater increase in T-cell responses compared to Comirnaty.
Please note that while neutralizing antibodies help in blocking infection, T-cell destroys infected cells.
This preliminary data is also supported by an initial data from another clinical study — UK COV-BOOST — that evaluated J&J’s COVID-19 vaccine’s booster dose in participants who have received immunization with Pfizer and BioNTech’s Comirnaty or AstraZeneca’s (AZN - Free Report) COVID-19 vaccine, ChAdOx1 nCov-19, in their primary vaccination regimen. Data from the UK COV-BOOST study also demonstrated an increase in both antibody and T-cell responses following J&J’s booster dose.
We note that AstraZeneca is one of the early players to market a COVID-19 vaccine in the world. However, AZN is yet to receive authorization for its vaccine in the United States. AstraZeneca produced the vaccine at cost amid the pandemic. The vaccine generated $1.05 billion in revenues for AstraZeneca in the first nine months of 2021.
This year so far, J&J’s shares have risen 1.2% compared with an increase of 12.3% for the industry.
J&J is a late entrant in the COVID-19 vaccine race. The company’s vaccine was first authorized for emergency use in the United States in February 2021. It expects $2.5 billion in revenues from the COVID-19 vaccine in 2021, significantly less than Pfizer’s $36 billion from its COVID-19 vaccine in the same period.
However, J&J’s booster dose was the first to receive emergency use authorization in the United States in October for all adults. Moreover, the recent preliminary data from the phase II study supports the use of J&J’s booster dose in people who have received initial vaccination with Comirnaty for better protection.
We note that the FDA had authorized the use of mix and match or heterologous administration of the booster doses in October that allows the administration of a booster dose of any authorized COVID-19 vaccine, irrespective of the primary vaccination regimen. This authorization of heterologous administration should ease the concerns related to the use of a different booster jab than the initial regimen.
With the majority of the population in the United States having received primary vaccination, the main revenue driver for the COVID-19 vaccine makers will come from the sale of booster doses. Clinical data supporting better protection with J&J’s booster dose may help the company drive the supply of booster doses higher next year. This may result in higher additional revenues for J&J from the COVID-19 vaccine next year.
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
Zacks Rank
J&J currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.